Raising the Bar for Advanced Knee Assessment Technology with Michelle Laflamme, CEO of Emovi

In this episode I spoke with Michelle Laflamme, CEO of Emovi, a
medical device company dedicated to developing and
commercializing advanced technologies for the assessment of knee
pain. Emovi began in 2008 when Michelle, a practicing lawyer at
the time, was reviewing the clinical evidence behind its
signature device, KneeKG, that helps clinicians to better
diagnose the root causes of knee pain and make data driven
treatment decisions. Michelle recognized that the technology
could fill gaps in the treatment pathway and bring huge value to
patients. Over the next few years, Michelle selected a team of
passionate and talented experts to take the company through
numerous validation studies (they have more than 100 peer
reviewed papers), to demonstrate effectiveness as a clinical
decision tool and to build strategic partnerships with key
stakeholders, including several university research centres and a
full clinical advisory board. Over 10,000 patients have used
KneeKG in their care pathways to help treat knee pain and get
back to their normal activity. With plans to expand access in
Canada and the US, many more patients will soon be using and
benefiting from the device. Her passion for entrepreneurship and
helping patients really stood out to me. She also spoke about her
work in mentoring other entrepreneurs through an accelerator she
founded, and through her roles on several boards. 


To learn even more about Emovi you can visit the company website
at emovi.ca. You can also follow the company and get updates on
its activity on Twitter @knee_KG , and follow Emovi on LinkedIn.